Last reviewed · How we verify
MS1819-SD
At a glance
| Generic name | MS1819-SD |
|---|---|
| Sponsor | AzurRx SAS |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis (PHASE2)
- Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs (PHASE2)
- A Phase IIa Study With Escalating Dose of MS1819-SD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MS1819-SD CI brief — competitive landscape report
- MS1819-SD updates RSS · CI watch RSS
- AzurRx SAS portfolio CI